"Benzenesulfonates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic salts and esters of benzenesulfonic acid.
| Descriptor ID |
D001557
|
| MeSH Number(s) |
D02.455.426.559.389.097 D02.886.645.600.080.050.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzenesulfonates".
Below are MeSH descriptors whose meaning is more specific than "Benzenesulfonates".
This graph shows the total number of publications written about "Benzenesulfonates" by people in this website by year, and whether "Benzenesulfonates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 2 | 1 | 3 |
| 2008 | 10 | 3 | 13 |
| 2009 | 8 | 5 | 13 |
| 2010 | 6 | 5 | 11 |
| 2011 | 10 | 12 | 22 |
| 2012 | 6 | 7 | 13 |
| 2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzenesulfonates" by people in Profiles.
-
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. AJR Am J Roentgenol. 2013 Jan; 200(1):120-6.
-
The role of STAT3 activation in modulating the immune microenvironment of GBM. J Neurooncol. 2012 Dec; 110(3):359-68.
-
APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival. PLoS One. 2012; 7(10):e47462.
-
Sorafenib in non-small cell lung cancer. Expert Opin Investig Drugs. 2012 Sep; 21(9):1417-26.
-
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer. 2012 Dec 15; 118(24):6152-61.
-
Molecular targeted therapy in acute myeloid leukemia. Hematology. 2012 Apr; 17 Suppl 1:S59-62.
-
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet. 2012; 8(3):e1002538.
-
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. J Mol Med (Berl). 2012 Oct; 90(10):1133-44.
-
Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncol Rep. 2012 May; 27(5):1303-11.
-
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell. 2012 Jan 17; 21(1):66-81.